EC Number   |
Application |
Reference |
|---|
   3.6.4.B10 | drug development |
development of cell-based CCT inhibitors using peptide reagents and HSF1A, a benzyl-pyrazole-based small molecule |
-, 749858 |
| 3.6.4.B10 | drug development |
development of small-molecule inhibitors of TRiC as potential antiviral therapeutics |
757782 |
| 3.6.4.B10 | drug development |
the enzyme is a target for the specific treatments of AML1-ETO-positive leukemia. AML1-ETO suppression by small interfering RNAs (siRNAs) supports normal myeloid differentiation of t(8,21)-positive leukemic cells which highlights AML1-ETO as a major clinical target to treat AML. Inhibition of HSP70/90, two major proteostasis regulators, has shown antileukemic effects in AML1-ETO positive cells. Moreover, the mammalian cytosolic chaperonin TRiC (or CCT) modulates the synthesis, folding and activity of AML1-ETO by direct association, primarily through its DNA-binding domain (AML1-175), and that HSP70 promotes this interaction |
756197 |
| 3.6.4.B10 | medicine |
subunit CCT2 is a chemotherapeutic target in uterine cancer |
749858 |
| 3.6.4.B10 | medicine |
TRiC is a therapeutic target in breast cancer |
756668 |
| 3.6.4.B10 | synthesis |
ApCpnB has both foldase and holdase activities and can be used as a powerful molecular machinery for the production of recombinant proteins as soluble and active forms in Escherichia coli |
712727 |
